Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127267102 | 12726710 | 2 | F | 20160903 | 20160906 | 20160908 | 20160930 | PER | US-ASTRAZENECA-2012BM06122 | ASTRAZENECA | 66.00 | YR | M | Y | 136.10000 | KG | 20160930 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127267102 | 12726710 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | U | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | |||||
| 127267102 | 12726710 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | U | A869551A | 21773 | 10 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | ||||
| 127267102 | 12726710 | 3 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | U | 21773 | 10 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | |||||
| 127267102 | 12726710 | 4 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | FN0142 | 0 | 2 | MG | /wk | |||||||
| 127267102 | 12726710 | 5 | C | NOVOLOG | INSULIN ASPART | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 6 | C | NOVOLIN | INSULIN HUMAN | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 7 | C | NPH INSULIN | INSULIN BEEF | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 8 | C | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 9 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 10 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 11 | C | QUINAPRIL. | QUINAPRIL | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 12 | C | METOPROLOL. | METOPROLOL | 1 | UNK | 0 | |||||||||||
| 127267102 | 12726710 | 13 | C | INSULIN | INSULIN NOS | 1 | Subcutaneous | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127267102 | 12726710 | 1 | Insulin-requiring type 2 diabetes mellitus |
| 127267102 | 12726710 | 2 | Insulin-requiring type 2 diabetes mellitus |
| 127267102 | 12726710 | 3 | Insulin-requiring type 2 diabetes mellitus |
| 127267102 | 12726710 | 4 | Type 2 diabetes mellitus |
| 127267102 | 12726710 | 5 | Diabetes mellitus |
| 127267102 | 12726710 | 6 | Diabetes mellitus |
| 127267102 | 12726710 | 7 | Diabetes mellitus |
| 127267102 | 12726710 | 8 | Diabetes mellitus |
| 127267102 | 12726710 | 9 | Diabetes mellitus |
| 127267102 | 12726710 | 10 | Diabetes mellitus |
| 127267102 | 12726710 | 13 | Type 2 diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127267102 | 12726710 | Blood creatine decreased | |
| 127267102 | 12726710 | Blood creatine increased | |
| 127267102 | 12726710 | Injection site haemorrhage | |
| 127267102 | 12726710 | Injection site nodule | |
| 127267102 | 12726710 | Injection site pain | |
| 127267102 | 12726710 | Mood altered | |
| 127267102 | 12726710 | Musculoskeletal pain | |
| 127267102 | 12726710 | Neovascularisation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127267102 | 12726710 | 1 | 200608 | 200609 | 0 | |
| 127267102 | 12726710 | 2 | 200609 | 0 | ||
| 127267102 | 12726710 | 3 | 200610 | 0 |